Company intelligence / Profile preview

Arch Oncology

Brisbane, California, United Statesorpha.net ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

AO-176, the company's lead product candidate, has demonstrated encouraging safety and evidence of anti-tumor activity in Phase 1 trials as a single agent. It is currently in Phase 1/2 clinical trials for solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies.

Therapeutic areas: Oncology
Modalities: Antibody therapiesanti-CD47 antibodies
Industry: Biotech

Drug pipeline

3 assets

AO-176

2 more assets in the full pipeline.

Request access →

Partnerships

Merck (collaboration on Phase 1/2 clinical trial of AO-176 in combination with KEYTRUDA)

Beyond the preview

Go deeper on Arch Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arch Oncology.

Explore the full profile